Pharmaceutical companies are strengthening domestic substitution of upstream equipment, and the pharmaceutical machine industry may benefit

Recently, Kangfang Bio announced that it has reached a cooperation with Shanghai Duoning Biotechnology Co.
, Ltd.
(referred to as "Duoning Bio")
.
The cooperation agreement shows that Abiotic Bio and Duoning Bio will cooperate on the development of new antibody drugs, give full play to the advantages of both parties in the upstream and downstream of the industrial chain, improve the efficiency of new drug research and development and production and reduce costs
.
At the same time, Kangfang Bio will also take a stake in Duoning Bio to deepen the cooperative relationship between the two parties
.
Pharmaceutical companies are strengthening domestic substitution of upstream equipment one after another (Source: Pharmaceutical Network
) Since 2019, the company has evolved from the original domestically produced serum-free medium and new single-use consumables platform to a one-stop supply platform
.
For this cooperation, the industry believes that, in addition to speeding up the integrated competitiveness of the research and development, production and sales of Kangfang biopharmaceuticals, it is also a manifestation of domestic innovative pharmaceutical companies strengthening the independent controllability of the supply chain and domestic substitution
.
In recent years, as upstream pharmaceutical equipment is still subject to the status quo of human beings, strengthening the independent controllability of the supply chain and domestic substitution has become the common expectation of domestic CXO companies and downstream pharmaceutical companies
.
At present, many innovative pharmaceutical companies have strengthened the pace of independent and controllable supply chains and domestic substitution
.
In this way, WuXi Biologics has established "two and a half" suppliers around the world.
The first two refer to the United States, Europe, and Japan, and half of the suppliers refer to domestic companies.
Risks are appropriately avoided at the business level
.
As more and more downstream pharmaceutical companies begin to consider purchasing domestic key equipment and related consumables, the industry believes that companies in the relevant supply chain will also usher in more development opportunities
.
Among them, the pharmaceutical equipment industry will undoubtedly be one of them
.
The pharmaceutical equipment/scientific instrument industry is the upstream of pharmaceutical companies, and it is also a very basic facility for the R&D and production of major pharmaceutical companies
.
Therefore, in the case of pharmaceutical companies strengthening domestic substitution of upstream equipment, the domestic pharmaceutical equipment industry will undoubtedly usher in more development opportunities
.
According to the author's understanding, in recent years, domestic pharmaceutical machines/scientific instruments have begun to accelerate the innovation to further promote the transformation of domestic pharmaceutical equipment from low-end to mid-to-high-end, as well as import substitution
.
For example, in recent years, Chutian Technology's product series has developed from several original product lines to nearly 20 product lines, from stand-alone sales to the provision of overall solutions for smart pharmaceutical industrial production equipment
.
Some products have reached the advanced level in Europe and entered the high-end field, opening up high-end import substitution
.
In addition, around the development strategy of "systematization, internationalization, and digital intelligence", Tofflon has been able to provide global customers with forward-looking and competitive pharmaceutical equipment, cell therapy equipment and other systematic solutions after years of struggle.
scheme
.
However, it should be noted that although some pharmaceutical equipment companies have been able to provide complete industrial chain services, in general, the supply chain services of the entire industry are not fully mature
.
Therefore, domestic pharmaceutical equipment enterprises must continue to improve their innovation capabilities and the ability to connect with advanced technologies in order to further enhance their competitiveness and compete with foreign companies
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.